CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing MP-101, a novel painkiller aimed at preventing and treating chemotherapy-induced peripheral sensory neuropathy (CIPN). By modulating glutamate signaling, MP-101 seeks to improve the quality of life for cancer patients experiencing debilitating pain from chemotherapy.
There will be over 18m new cases of cancer worldwide in 20181, out of which about 3,7m in Europe alone.
Studies estimate that up to 40% of all cancer patients develop chemotherapy-induced peripheral sensory neuropathy (CIPN), meaning over 1,6m patients in EU and 7,2m world-wide may experience CIPN each year.
This group is only growing in number, due to the constant growth in new cases of diagnosed cancer.
The new immuno-oncology drugs are increasingly being used in combination with chemotherapy.…
METYS PHARMACEUTICALS AG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
